network member

Duke Cancer Institute

Durham, NC

About Network Member

Website: Duke Cancer Institute

https://dukecancerinstitute.org

Currently Enrolling

HCRN-BRE18-360

Phase I/II Study of Stereotactic Radiosurgery With Concurrent Administration of DNA Damage Response (DDR) Inhibitor (OLAparib) Followed by Adjuvant Combination of DuRvalumab (MEDI4736) and Physician’s Choice Systemic Therapy in Subjects With BreAst Cancer Brain Metastases

Cancer areas:Breast

Cleveland Clinic Cancer Center

Duke Cancer Institute

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Memorial Breast Cancer Center at Memorial Regional Hospital

Memorial Sloan Kettering Cancer Center

University of North Carolina Lineberger Comprehensive Cancer Center

See clinicaltrials.gov

Currently Enrolling

HCRN-BRE21-516

BRIDGET: Secondary BRain metastases prevention after Isolated intracranial progression on Trastuzumab/Pertuzumab or T-DM1 in patients with aDvanced human epidermal Growth factor receptor 2+ brEast cancer with the addition of Tucatinib

Cancer areas:Breast

Dana-Farber Cancer Institute

Duke Cancer Institute

MD Anderson Cancer Center

Novant Health Oncology Specialists

Providence Cancer Institute

Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

The Ohio State University

UC San Francisco

University of Michigan Rogel Cancer Center

See clinicaltrials.gov

Currently Enrolling

TBCRC047

Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study

Hope Rugo

Cancer areas:Breast

Dana-Farber Cancer Institute

Duke Cancer Institute

Georgetown Lombardi Comprehensive Cancer Center

Mayo Clinic

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

The University of Chicago Medicine Comprehensive Cancer Center

UC San Francisco

University of Alabama at Birmingham Comprehensive Cancer Center

University of North Carolina Lineberger Comprehensive Cancer Center

Vanderbilt-Ingram Cancer Center

See clinicaltrials.gov

Enrollment Closed

HCRN-LUN21-497

A Phase II Study of GT103 in Combination with Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer

Cancer areas:Lung

Barbara Ann Karmanos Cancer Center

Duke Cancer Institute

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Summit Health Cancer Center

University of Illinois Cancer Center

University of Virginia Cancer Center

See clinicaltrials.gov